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Parkinson disease (PD) is a chronic, progressive neurological disease that is associated
with a loss of dopaminergic neurons in the substantia nigra pars compacta of the brain.
The molecular mechanisms underlying the loss of these neurons still remain elusive.
Oxidative stress is thought to play an important role in dopaminergic neurotoxicity.
Complex I deficiencies of the respiratory chain account for the majority of unfavorable
neuronal degeneration in PD. Environmental factors, such as neurotoxins, pesticides,
insecticides, dopamine (DA) itself, and genetic mutations in PD-associated proteins
contribute to mitochondrial dysfunction which precedes reactive oxygen species
formation. In this mini review, we give an update of the classical pathways involving
these mechanisms of neurodegeneration, the biochemical and molecular events that
mediate or regulate DA neuronal vulnerability, and the role of PD-related gene products in
modulating cellular responses to oxidative stress in the course of the neurodegenerative
process.
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Introduction
Parkinson’s disease (PD) is associated with the selective loss of dopamine (DA) neurons in the
substantia nigra pars compacta (SNpc) and DA levels in the corpus striatum of the nigrostriatal DA
pathway in the brain. This loss of DA causes a deregulation in the basal ganglia circuitries that leads
to the appearance of motor symptoms such as bradykinesia, resting tremor, rigidity, and postural
instability as well as non-motor symptoms such as sleep disturbances, depression, and cognitive
deﬁcits (Rodriguez-Oroz et al., 2009). The exact etiology of PD still remains elusive and the precise
mechanisms that cause this disease remain to be identiﬁed (Obeso et al., 2010). At the cellular level,
PD is related to excess production of reactive oxygen species (ROS), to alterations in catecholamine
metabolism, to modiﬁcations in mitochondrial electron transporter chain (METC) function or to
enhancement of iron deposition in the SNpc. The failure of normal cellular processes that occur
in relation to the aging process are also believed to contribute to the increased vulnerability of DA
neurons (Schapira and Jenner, 2011; Rodriguez et al., 2014).
While the familial forms of PD, that have been described, involve mutations in a number
of genes (Kieburtz and Wunderle, 2013; Trinh and Farrer, 2013), mitochondrial dysfunction,
neuroinﬂammation and environmental factors are increasingly appreciated as key determinants
of dopaminergic neuronal susceptibility in PD, and are a feature of both familial and sporadic
forms of the disease (Ryan et al., 2015). In both cases, oxidative stress is thought to be the
common underlying mechanism that leads to cellular dysfunction and, eventual cell death. ROS
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are continuously produced in vivo by all body tissues. However,
oxidative stress occurs when there is an imbalance between
ROS production and cellular antioxidant activity. Oxidants
and superoxide radicals are produced as products of oxidative
phosphorylation, making mitochondria the main site of ROS
generation within the cell. ROS can aﬀect mitochondrial DNA
which can cause modulations in the synthesis of METC
components like adenosine triphosphate (ATP) production as
well as the leakage of ROS into the cell’s cytoplasm (Brieger et al.,
2012).
Although the precise mechanism corresponding to ROS
generation related to PD is still unknown, in this review, we
summarize the major sources of oxidative stress generated by
the DA neurons, like DAmetabolism, mitochondrial dysfunction,
and neuroinﬂammation (Figure 1).
Dopamine Metabolism
Selective degeneration of the DA neurons of the SNpc suggests
that DA itself may be a source of oxidative stress (Segura-
Aguilar et al., 2014). DA is synthesized from tyrosine by tyrosine
hydroxylase (TH) and aromatic amino acid decarboxylase.
Following this, DA is stored in synaptic vesicles after uptake
by the vesicular monoamine transporter 2 (VMAT2). However,
when there is an excess amount of cytosolic DA outside of
the synaptic vesicle in damaged neurons, i.e., after L-DOPA
treatment, DA is easily metabolized via monoamine oxidase
(MAO) or by auto-oxidation to cytotoxic ROS (Zucca et al.,
2014). For example, mishandling of DA in mice with reduced
VMAT2 expression was suﬃcient to cause DA-mediated toxicity
and progressive loss of DA neurons (Caudle et al., 2007).
This oxidative process alters mitochondrial respiration and
induces a change in the permeability transition pores in brain
mitochondria (Berman and Hastings, 1999). Also, the auto-
oxidation of DA produces electron-deﬁcient DA quinones or
DA semiquinones (Sulzer and Zecca, 2000). Some studies
have demonstrated a regulatory role for quinone formation
in DA neurons in the L-DOPA-treated PD model induced by
neurotoxins and in methamphetamine neurotoxicity (Asanuma
et al., 2003; Miyazaki et al., 2006; Ares-Santos et al., 2014). DA
quinones can modify a number of PD-related proteins, such
as α-synuclein (α-syn), parkin, DJ-1, Superoxide dismutase-2
(SOD2), and UCH-L1 (Belluzzi et al., 2012; Girotto et al., 2012;
da Silva et al., 2013; Hauser et al., 2013; Toyama et al., 2014; Zhou
et al., 2014) and have been shown to cause inactivation of the
DA transporter (DAT) and the TH enzyme (Kuhn et al., 1999;
Whitehead et al., 2001), as well as mitochondrial dysfunction
(Lee et al., 2003), alterations of brain mitochondria (Gluck and
Zeevalk, 2004) and dysfunction in Complex I activity (Jana et al.,
2007, 2011; Van Laar et al., 2009). Additionally, DA quinones
can be oxidized to aminochrome, whose redox-cycling leads to
the generation of the superoxide radical and the depletion of
cellular nicotinamide adenine dinucleotide phosphate-oxidase
(NADPH), which ultimately forms the neuromelanin (Sulzer
et al., 2000) known to be accumulated in the SNpc of the human
brain (Ohtsuka et al., 2013, 2014; Plum et al., 2013).
Signiﬁcant increases in cysteinyl adducts of L-DOPA, DA, and
DOPAC have been found in substantia nigra of PD patients,
suggesting the cytotoxic nature of DA oxidation (Spencer et al.,
1998). Also, DA terminals actively degenerated proportionally to
increased levels of DA oxidation following a single injection of
DA into the striatum (Rabinovic et al., 2000). Recently, it has
been shown that increased uptake of DA through the DAT in
mice results in oxidative damage, neuronal loss andmotor deﬁcits
(Masoud et al., 2015).
Mitochondrial Dysfunction
Mitochondrial dysfunction is closely related to increased ROS
formation in PD (Schapira, 2008). Oxidative phosphorylation is
the mainmechanism providing energy to power neural activity in
which the mitochondria use their structure, enzymes, and energy
released by the oxidation of nutrients to form ATP (Hall et al.,
2012). Consequently, this metabolic pathway is the main source
of superoxide and hydrogen peroxide, which, at the same time,
lead to propagation of free radicals contributing to the disease.
Complex I deﬁciencies of the respiratory chain account for
the majority of unfavorable neural apoptosis generation and is
considered one of the primary sources of ROS in PD. Complex I
inhibition results in an enhanced production of ROS, which, in
turn, will inhibit complex I. Reduction in complex I activity in
the SNpc of patients with sporadic PD has been well described
(Schapira et al., 1990; Hattori et al., 1991; Hattingen et al., 2009).
Additionally, mitochondrial complex I deﬁciency in diﬀerent
brain regions (Mizuno et al., 1989; Parker et al., 2008), ﬁbroblasts
(Mytilineou et al., 1994), blood platelets (Krige et al., 1992;
Blandini et al., 1998), skeletal muscle (Blin et al., 1994), and
lymphocytes (Yoshino et al., 1992; Haas et al., 1995) of PD
patients has been shown before as well.
As such, complex I inhibitors like 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) or rotenone show preferential
cytotoxicity to the DA neurons (Blesa and Przedborski, 2014).The
mechanism by which MPTP crosses the blood–brain barrier
and is oxidized to 1-methyl-4-phenylpyridinium (MPP+) is well
known (Blesa and Przedborski, 2014). The MPP+ accumulates
in the mitochondria where it inhibits complex I in the METC,
therefore disrupting the ﬂow of electrons along the METC,
which results in decreased ATP production and increased
generation of ROS (Mizuno et al., 1987). Like MPTP, rotenone
is another mitochondrial complex I inhibitor. Interestingly,
rotenone toxicity is involved in oxidative damage to proteins and
Lewy body-like inclusions (Betarbet et al., 2000; Sherer et al.,
2003a,b; Greenamyre et al., 2010). The events downstream to
complex I inhibition that lead to neuronal cell death by these
toxins are still unknown (Schapira, 2010).
Other evidence for mitochondrial dysfunction related to
oxidative stress and DA cell damage comes from ﬁndings that
mutations in genes of proteins like α-syn, parkin, DJ-1, or
PINK are linked to familial forms of PD. The convergence
of all of these proteins on mitochondrial dynamics uncovers
a common function in the mitochondrial stress response that
might provide a potential physiological basis for the pathology
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FIGURE 1 | Suggested physiological processes related to pathogenesis
of Parkinson’s disease (PD). Different pathways and their dysfunctions
resulting from genetic modifications in PD-related genes and lead to an
increased oxidative stress. Mutations or altered expression of these proteins
result in mitochondrial impairment, oxidative stress, and protein misfolding. Also,
dopamine metabolism may be oxidized to reactive dopamine quinones
contributing to increased levels of reactive oxygen species. α-Synuclein
becomes modified and accelerate its aggregation. Increased oxidative stress
provokes impaired function of the UPS that degrades misfolded or damaged
proteins and hereby further affecting cell survival. Environmental toxins impair
mitochondrial function, increase the generation of free radicals, and lead to
aggregation of proteins, including α-synuclein. Mitochondrial dysfunction by
complex I inhibition affects by adding an increase in oxidative stress and a
decline in ATP production, leading to damage of intracellular components and to
cell death. Also, neuroinflammatory mechanisms might contribute to the
cascade of consequences leading to cell death. In summary, all these several
cellular mechanisms attributed to oxidative stress are implicated in the selective
degeneration of dopaminergic neurons.
of PD (Norris et al., 2015; van der Merwe et al., 2015). Overall,
these observations show that mutations in these genes aﬀect
mitochondrial function and integrity and, are associated with
increases in oxidative stress (Zuo and Motherwell, 2013). ROS
inﬂuence proteasomal, lysosomal, and mitochondrial function,
which, in turn, regulate the cellular response to oxidative damage
(Cook et al., 2012). The correct elimination of damaged proteins
by eﬀective proteolysis and the synthesis of new and protective
proteins are vital in the preservation of brain homeostasis during
periods of increased levels of ROS. Consequently, this can lead
to protein misfolding (i.e., α-syn), preventing the ability of some
of these proteins to be unfolded and degraded by the systems
that regulate protein clearance, like the ubiquitin proteasome
system or autophagy. Indeed, protein misfolding, together with
the dysfunction of these protein degradation systems, may play a
key role in the appearance of deleterious events implicated in the
neurodegenerative process of PD (Schapira et al., 2014).
Parkin and PINK1 are localized in the mitochondria and
their functions are tightly connected to the normal functioning
of the mitochondria (Scarﬀe et al., 2014). PINK1 accumulates
on the outer membrane of damaged mitochondria and recruits
Parkin to the dysfunctional mitochondrion (Pickrell and Youle,
2015). In humans with parkin mutations, mitochondrial complex
I activity is impaired (Müftüoglu et al., 2004). Overexpression
of parkin in mice reduced DA neuronal cell loss induced by
MPTP through the protection of mitochondria and the reduction
of α-syn (Bian et al., 2012). On the other hand, parkin KO
mice showed decreased amounts of several proteins that are
involved in mitochondrial function and oxidative stress as well
as increases in protein oxidation and lipid peroxidation (Palacino
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et al., 2004). Also, Drosophila, lacking, or deﬁcient in parkin,
exhibit mitochondrial deﬁcits and high vulnerability to oxidative
stress (Saini et al., 2010). PINK1 mutations in humans lead
to mitochondrial defects and respiratory chain abnormalities
(Hoepken et al., 2007; Piccoli et al., 2008). PINK1 KO in human
and mouse DA neurons causes decreases in membrane potential
and increases in ROS generation (Wood-Kaczmar et al., 2008).
The decrease in mitochondrial membrane potential is not due to
a proton leak, but to respiratory chain defects like complex I and
complex III deﬁciency (Amo et al., 2011, 2014). Therefore, PINK1
is required for maintaining normal mitochondrial morphology
of SNpc DA neurons in culture and exerts its neuroprotective
eﬀect by inhibiting ROS formation (Wang et al., 2011). In animal
models, studies show that the lack of PINK1 resulted in abnormal
mitochondrial morphology, loss of SNpc DA neurons, reduction
in complex I activity, and enhanced vulnerability to oxidative
stress (Clark et al., 2006; Kitada et al., 2007; Gautier et al., 2008).
These defects can be ameliorated and rescued by the enhanced
expression of parkin (Yang et al., 2006; Exner et al., 2007). This
last scenario seems to involve PINK1 and Parkin in a common
pathway that regulatesmitochondrial physiology and cell survival
in which PINK1 seems to be functioning upstream of Parkin, at
least as observed inDrosophila disease models (Clark et al., 2006).
α-syn is a soluble protein that is highly enriched in the
presynaptic terminals of neurons. Accumulation of α-syn as
intracellular ﬁlamentous aggregates is a pathological feature
of both sporadic and familial PD (Goedert et al., 2013).
Accumulation of wild-type α-syn in DA neurons reduced
mitochondrial complex I activity, elevated ROS production
leading to cell death (Martin et al., 2006). It has been
shown that α-syn inclusions elevate dendritic mitochondrial
oxidative stress in DA neurons (Dryanovski et al., 2013). This
mitochondrial dysfunction occurs many months before the
occurrence of striatal DA loss (Subramaniam et al., 2014).
The nuclear translocation of α-syn increases susceptibility of
MES23.5 cells to oxidative stress (Zhou et al., 2013). Exposure
to rotenone or other stimuli that promote ROS formation
and mitochondrial alterations correlate well with mutant α-syn
phosphorylation at Ser129 (Perfeito et al., 2014). Oxidative
stress promotes uptake, accumulation, and oligomerization of
extracellular α-syn in oligodendrocytes (Pukass and Richter-
Landsberg, 2014) and induces posttranslational modiﬁcations of
α-syn which can increase DA toxicity (Xiang et al., 2013). It has
been suggested that the NADPH oxidases, which are responsible
for ROS generation, could be major players in synucleinopathies
(Cristóvão et al., 2012).
DJ-1 is another gene reported to cause a familial early onset
PD (Puschmann, 2013). DJ-1 binds to subunits of mitochondrial
complex I and regulates its activity (Hayashi et al., 2009).
Although a portion of DJ-1 is present in mitochondria matrix
and inter-membrane space (Zhang et al., 2005), the degree
of translocation of DJ-1 into mitochondria is stimulated by
oxidative stress (Canet-Avilés et al., 2004). Mitochondrial-
targeted sequence-conjugated DJ-1 has been shown to be more
protective against oxidative stress-induced cell death (Junn et al.,
2009). DJ-1 KO mice displayed nigrostriatal DA neuron loss
(Goldberg et al., 2005). Also, these DJ-1 KO mice showed altered
mitochondrial respiration and morphology, reduced membrane
potential, and accumulation of defective mitochondria (Irrcher
et al., 2010; Krebiehl et al., 2010; Giaime et al., 2012). These
defects can be reversed by DJ-1 overexpression, which points
to the speciﬁc role of DJ-1 in mitochondrial function (Heo
et al., 2012). Recently, following oxidative stress, DJ-1 was shown
to be involved in the oxidative stress response that leads to
the upregulation of the proteasome, thus inhibiting its activity
and rescuing partially unfolded proteins from degradation
(Moscovitz et al., 2015).
Neuroinflammation
Neuronal loss in PD is associated with chronic neuroinﬂam-
mation, which is controlled primarily by microglia, the major
resident immune cells in the brain (Barcia et al., 2003) and, to
a lesser extent, by astrocytes and oligodendrocytes (Perry, 2012).
Microglial activation has been found with a greater density in
the SNpc (Lawson et al., 1990) and in the olfactory bulb of
both sporadic and familial PD patients (McGeer et al., 1988;
Doorn et al., 2014a,b). Additionally, activated microglia have
been found in the SNpc and in the striatum of PD animal models
(Pisanu et al., 2014; Stott and Barker, 2014) and have been
associated with diﬀerent PD-associated gene/proteins like α-syn
or LRRK2 (Daher et al., 2014; Sacino et al., 2014). In response to
certain environmental toxins and endogenous proteins, microglia
can shift to an over-activated state and release ROS which can
cause neurotoxicity (Block et al., 2007). Accumulating evidence
indicates that activation of diﬀerent enzymes like NADPH
oxidase (NOX2) in microglia is neurotoxic not only through
the production of extracellular ROS that damage neighboring
neurons but also through the initiation of redox signaling in
microglia that ampliﬁes the pro-inﬂammatory response (Surace
and Block, 2012).
Neuromelanin confers the dark pigmentation that is produced
from DA oxidation and is so characteristic of the SNpc
appearance. High levels of catecholamine metabolism in the
midbrain are associated with increased levels of neuromelanin
in the same region and, it is neuromelanin that is thought
to be one of the molecules responsible for inducing chronic
neuroinﬂammation in PD. Neuromelanin released from dying
DA neurons in the SNpc activate microglia, increasing the
sensitivity of DA neurons to oxidative stress-mediated cell death
(Halliday et al., 2005; Li et al., 2005; Beach et al., 2007; Zhang et al.,
2009). The ability of neuromelanin to interact with transition
metals, especially iron, and to mediate intracellular oxidative
mechanisms have received particular attention. Increased levels
of iron result in increased ROS and increased oxidative stress and
has been shown to be involved in aging and PD. Iron homeostasis
is modulated by angiotensin in DA neurons and microglia, and
glial cells play an essential role in the eﬃcient regulation of this
balance (Garrido-Gil et al., 2013).
Dopamine neurons containing neuromelanin are especially
more susceptible, indicating a possible role for neuromelanin
in MPTP-toxicity (Herrero et al., 1993). MPTP induces a
glial response, increased levels of inﬂammatory cytokines and
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microglial activation in mice (Członkowska et al., 1996; Jackson-
Lewis and Smeyne, 2005) and monkeys (Barcia et al., 2004,
2009). Angiotensin is one of the most important inﬂammation
and oxidative stress inducers, and produces ROS by activation
of the NADPH-oxidase complex. It has been suggested that the
inﬂammatory response in the MPTPmodel could be mediated by
brain angiotensin and microglial NADPH-derived ROS (Joglar
et al., 2009). Moreover, oral treatment with NADPH oxidase
antagonists mitigates the clinical and pathological features of
parkinsonism in the MPTP marmoset model (Philippens et al.,
2013). Also, microglia play an important role in mediating
rotenone-induced neuronal degeneration through NADPH (Gao
et al., 2003, 2011; Pal et al., 2014). Rotenone increased microglial
activation in both the SNpc and striatum in rats (Sherer et al.,
2003a), activated microglia via the NF-κB signaling pathway
(Gao et al., 2013) and induced neuronal death by the microglial
phagocytosis of neurons (Emmrich et al., 2013).
Parkinson’s disease-associated proteins like α-syn, parkin,
LRRK2, and DJ-1 have also been reported to activate microglia
(Wilhelmus et al., 2012). Extracellular α-syn released from
neuronal cells is an endogenous agonist for Toll-like receptor 2
(TLR2), which activates the microglial inﬂammatory responses
(Kim et al., 2013a). An increased number of activated
microglia and increased levels of TNF-α mRNA and protein
were detected in the striatum and in the SNpc of mice
over-expressing WT human α-syn (Watson et al., 2012).
Moreover, in α-syn KO mice, microglia secreted higher levels
of proinﬂammatory cytokines, TNF alpha and IL-6 (interleukin-
6) compared to WT mice (Austin et al., 2006). Intracerebral
injection of recombinant amyloidogenic or soluble α-syn
induces extensive α-syn intracellular inclusion pathology that
is associated with a robust gliosis (Sacino et al., 2014). LRRK2
increases proinﬂammatory cytokine release from activated
primary microglial cells which results in neurotoxicity (Gillardon
et al., 2012). In contrast, LRRK2 inhibition attenuates microglial
inﬂammatory responses (Moehle et al., 2012). Additionally,
lipopolysaccharide induces LRRK2 up-regulation and microglial
activation in mouse brains (Li et al., 2014) but they down
regulated Parkin expression via NF-κB (Tran et al., 2011).
Abnormal glial function is critical in parkin mutations, increasing
vulnerability to inﬂammation-related nigral degeneration in PD
(Frank-Cannon et al., 2008) and its role increases with aging
(Solano et al., 2008). DJ-1 expression is up-regulated in reactive
astrocytes in PD patients (Bandopadhyay et al., 2004). DJ-1
negatively regulates inﬂammatory responses of astrocytes and
microglia by facilitating the interaction between STAT1 and its
phosphatase SHP-1 (Kim et al., 2013b). Astrocyte cultures from
DJ-1 KOmice treated with lipopolysaccharide have increased NO
production and an up-regulation of diﬀerent pro-inﬂammatory
mediators like COX-2 and IL-6 (Waak et al., 2009).
Conclusion
The elements that potentially cause oxidative stress in PD are
still unknown. DA metabolism, mitochondrial dysfunction and
neuroinﬂammation all play critical roles in the etiology of this
disease. Exposure to environmental factors or mutations in PD-
associated genes of patients with either sporadic or familial PD
may cause mitochondrial dysfunction that ultimately results in
PD. All of these share common linkages and inﬂuence each
other greatly. Limiting the early inﬂammatory response will
reduce further both elevated oxidative stress and microglial
activation that are key to slowing the death of the neurons
in the SNpc. Development of potential drugs able to delay
the neurodegenerative process is crucial to ameliorating the
deleterious eﬀects of oxidative stress in neurodegenerative
diseases. Neuroprotective therapies will need to target multiple
pathological pathways such as mitochondrial dysfunction and
neuroinﬂammation in the next few years.
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